C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of$ 0.47. This compares to a loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.38%. A quarter ago, it was expected that this company would post a loss of$ 0.38 per share when it actually produced a loss of $0.37, delivering a surprise of +2.63%.Over the last four quarters, the company has ...